Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings.
作者信息
Egilman Alexander C, Van de Wiele Victor L, Rome Benjamin N, Darrow Jonathan J, Tu S Sean, Kesselheim Aaron S, Sarpatwari Ameet
机构信息
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
West Virginia University College of Law, Morgantown.
出版信息
JAMA Intern Med. 2023 Jan 1;183(1):82-84. doi: 10.1001/jamainternmed.2022.5419.
Abstract
摘要
相似文献
1
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings.
JAMA Intern Med. 2023 Jan 1;183(1):82-84. doi: 10.1001/jamainternmed.2022.5419.
2
Savings Associated With "Skinny Label" Biosimilars.
JAMA Intern Med. 2023 Jan 1;183(1):84. doi: 10.1001/jamainternmed.2022.5418.
3
The Inflation Reduction Act: A boon for the generic and biosimilar industry.
J Clin Pharm Ther. 2022 Nov;47(11):1738-1751. doi: 10.1111/jcpt.13783. Epub 2022 Oct 7.
4
Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
Clin Pharmacol Ther. 2021 Oct;110(4):1050-1056. doi: 10.1002/cpt.2322. Epub 2021 Jul 6.
5
10 years of biosimilars: lessons and trends.
Nat Rev Drug Discov. 2020 Jun;19(6):375. doi: 10.1038/d41573-020-00081-5.
6
Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):447-454. doi: 10.1080/14737167.2018.1476142. Epub 2018 May 18.
7
Optimizing use and addressing challenges to uptake of biosimilars.
Am J Manag Care. 2018 Nov;24(21 Suppl):S457-S461.
8
Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
Am J Health Syst Pharm. 2021 Jan 22;78(3):216-221. doi: 10.1093/ajhp/zxaa376.
9
The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
Ophthalmology. 2023 Sep;130(9):966-972. doi: 10.1016/j.ophtha.2023.04.019. Epub 2023 Apr 26.
10
A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
J Manag Care Spec Pharm. 2017 Dec;23(12):1234-1244. doi: 10.18553/jmcp.2017.23.12.1234.
引用本文的文献
1
Frequency of first generic drugs approved through "skinny labeling," 2021 to 2023.
J Manag Care Spec Pharm. 2025 Apr;31(4):343-350. doi: 10.18553/jmcp.2025.31.4.343.
2
Monoclonal antibody biosimilars for cancer treatment.
iScience. 2024 May 24;27(6):110115. doi: 10.1016/j.isci.2024.110115. eCollection 2024 Jun 21.
本文引用的文献
1
Projected US savings from biosimilars, 2021-2025.
Am J Manag Care. 2022 Jul;28(7):329-335. doi: 10.37765/ajmc.2022.88809.
2
The characteristics of patents impacting availability of biosimilars.
Nat Biotechnol. 2022 Jan;40(1):22-25. doi: 10.1038/s41587-021-01170-5.
3
A Court Decision on "Skinny Labeling": Another Challenge for Less Expensive Drugs.
JAMA. 2021 Oct 12;326(14):1371-1372. doi: 10.1001/jama.2021.0006.
4
Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States.
JAMA Intern Med. 2021 Jul 1;181(7):995-997. doi: 10.1001/jamainternmed.2021.0484.
5
Biosimilar Cost Savings in the United States: Initial Experience and Future Potential.
Rand Health Q. 2018 Mar 30;7(4):3. eCollection 2018 Mar.
Zotero 插件